Literature DB >> 10501423

Prognosis in children with rheumatic diseases: justification for consideration of new therapies.

R E Petty1.   

Abstract

It is evident that current approaches to the treatment of childhood arthritis, although much improved in the past decade, are still insufficient to halt the destructive progress of these diseases in many children. Furthermore, the treatment itself is associated with toxicity which may be prohibitive. The need for new and innovative treatments is urgent. ABMT is one possible avenue that offers hope to children with severe unresponsive disease. It will be important to select carefully those children who are likely to benefit from such an approach. An appreciation of the prognosis and possible predictors of disease severity should aid in this task.

Entities:  

Mesh:

Year:  1999        PMID: 10501423     DOI: 10.1093/rheumatology/38.8.739

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  19 in total

Review 1.  Autologous haematopoietic stem cell transplantation in juvenile idiopathic arthritis.

Authors:  L R Wedderburn; M Abinun; P Palmer; H E Foster
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 2.  [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].

Authors:  G Horneff
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

Review 3.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 4.  [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)].

Authors:  G Horneff
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

Review 5.  Stem cell therapy in autoimmune rheumatic diseases: a comprehensive review.

Authors:  Bin Liu; ShangAn Shu; Thomas P Kenny; Christopher Chang; Patrick S C Leung
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 6.  Hematopoietic stem cell transplantation for auto immune rheumatic diseases.

Authors:  Subramanian Ramaswamy; Sandeep Jain; Vinod Ravindran
Journal:  World J Transplant       Date:  2016-03-24

7.  Articular damage in adults with juvenile idiopathic arthritis.

Authors:  Eda Gurcay; Emel Eksioglu; Serdil Yuzer; Ajda Bal; Aytul Cakci
Journal:  Rheumatol Int       Date:  2008-10-14       Impact factor: 2.631

8.  Protocol for the Foot in Juvenile Idiopathic Arthritis trial (FiJIA): a randomised controlled trial of an integrated foot care programme for foot problems in JIA.

Authors:  Gordon J Hendry; Deborah E Turner; John McColl; Paula K Lorgelly; Roger D Sturrock; Gordon F Watt; Michael Browne; Janet Gardner-Medwin; Lorraine Friel; Jim Woodburn
Journal:  J Foot Ankle Res       Date:  2009-06-30       Impact factor: 2.303

Review 9.  The German etanercept registry for treatment of juvenile idiopathic arthritis.

Authors:  G Horneff; H Schmeling; T Biedermann; I Foeldvari; G Ganser; H J Girschick; T Hospach; H I Huppertz; R Keitzer; R M Küster; H Michels; D Moebius; B Rogalski; A Thon
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

10.  Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept.

Authors:  Renee F Robinson; Milap C Nahata; John R Hayes; Robert Rennebohm; Gloria Higgins
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.